Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2014; 112(02): 421-423
DOI: 10.1160/TH14-01-0050
DOI: 10.1160/TH14-01-0050
Letters to the Editor
Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels
Authors
Further Information
Publication History
Received:
18 January 2014
Accepted after minor revsion:
27 February 2014
Publication Date:
21 November 2017 (online)
-
References
- 1 Baglin T, Hillarp A, Tripodi A. et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760.
- 2 Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159: 427-429.
- 3 Hillarp A, Baghaei F, Fagerberg B. et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 09: 133-139.
- 4 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure riva-roxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
- 5 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
- 6 Rohde G. Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
- 7 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
- 8 Mueck W, Lensing AW, Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
- 9 Douxfils J, Tamigniau A, Chatelain B. et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
- 10 Patel JP, Roberts LN, Chitongo PB. et al. More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban - early experience from King’s College Hospital. Br J Haematol 2013; 162: 717-718.
- 11 van Veen JJ, Smith J, Kitchen S. et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 2013; 160: 859-861.